section name header

Pronunciation

ves-TRON-i-dase al-FA vjbk

Classifications

Therapeutic Classification: replacement enzyme

Pharmacologic Classification: enzymes

Indications

REMS


Action

  • Recombinant form of human beta-glucuronidase (GUS) which is taken up by lysosomes and causing catabolism of accumulated (GAGs) in affected tissues.
Therapeutic effects:
  • Improved motor and pulmonary function and reduced liver and spleen volumes.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Eliminated by proteolytic degradation into small peptides and amino acids.

Half-Life: 2.6 hr

Time/Action Profile

(serum concentrations)

ROUTEONSETPEAKDURATION
IVunknownunknownunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: peripheral edema

Derm: pruritus, rash

GI: diarrhea

Misc: ANAPHYLAXIS, extravasation, infusion site reactions

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Mepsevii

Pot. Nursing Diagnoses

Code

NDC Code